Objective: Local vancomycin treatment has been shown to decrease sternal wound complication rates. Whether a similar effect can be achieved at other surgical sites is unknown. This study investigates the effect of local vancomycin on inguinal wound complication rates after vascular procedures. Methods: Retrospective analysis was performed on 454 patients who underwent open aortofemoral or infrainguinal vascular procedures between 2006 and 2011. Patients received preoperative systemic antibiotics either alone (group A) or in conjunction with intraoperative wound application of vancomycin powder and irrigation (group B). Inguinal wound infection and dehiscence over a 30-day period were recorded. Fisher exact test and multivariate regression analyses were performed. Results: There were 211 patients in group A and 243 patients in group B. Both groups had similar demographics and operative characteristics. There was a small but statistically significant decrease in the 30-day incidence of overall wound infections (25.1% vs 17.2%; P [ .049) for group B patients. This was primarily due to a decreased rate in superficial infections (18.9% vs 11.5%; P [ .033). No significant difference in the incidence of deep wound infections (6.1% vs 5.7%; P [ .692) or overall dehiscence rates (22.2% vs 17.7%; P [ .239) was detected. On multivariate analysis, history of chronic obstructive pulmonary disease and increased body mass index significantly increased risk of both infection and dehiscence. Medically optimized coronary artery disease was associated with less risk for dehiscence. Conclusions: Addition of intraoperative local vancomycin did not improve the rates of inguinal wound dehiscence or deep infections but had a positive impact on superficial wound infections. (J Vasc Surg 2013;57:1079-83.) Inguinal wound complications occurring after vascular procedures contribute significantly to postoperative morbidity and may substantially increase health care costs. These complications range from superficial and deep surgical site infections to dehiscence, and they are most commonly due to gram-positive bacteria, such as Staphylococcus aureus or Staphylococcus epidermis. Methicillinresistant Staphylococcus aureus (MRSA) is emerging as the prevalent pathogen in these infections, with involvement in more than one-third of cases.
Inguinal wound complications occurring after vascular procedures contribute significantly to postoperative morbidity and may substantially increase health care costs. These complications range from superficial and deep surgical site infections to dehiscence, and they are most commonly due to gram-positive bacteria, such as Staphylococcus aureus or Staphylococcus epidermis. Methicillinresistant Staphylococcus aureus (MRSA) is emerging as the prevalent pathogen in these infections, with involvement in more than one-third of cases. 1 In an attempt to decrease the rate of these complications, surgeons in a variety of operative fields have used intraoperative local antibiotic treatment before wound closure. Although such treatment has been shown to decrease sternal wound complication rates in median sternotomy wounds, whether a similar effect can be achieved at other surgical sites remains unclear. 2 This study investigates the effect of intraoperative local vancomycin treatment on 30-day inguinal wound complication rates after vascular procedures.
METHODS
We conducted a retrospective review of 454 consecutive patients who underwent open aortofemoral or infrainguinal procedures between 2006 and 2011. Patients with already infected groin wounds or infected prosthetic conduits were excluded from the study. All patients received intravenous weight-based prophylactic antibiotic therapy within 1 hour before incision, and this therapy was redosed according to protocol for lengthier cases. Perioperative antibiotics were continued for the first 24 hours postoperatively. Patients received preoperative systemic antibiotics either alone (group A) or in conjunction with intraoperative wound application of 1 g of vancomycin powder and irrigation (group B) at the surgeon's discretion. Half of the dose was dispersed in powder form on the inguinal wound bed before closure, and the other half was mixed with 500 cc of normal saline and used to irrigate the wound throughout the procedure.
Baseline demographics, clinical characteristics, and operative details were obtained from the medical records. Past medical history of coronary artery disease (CAD), diabetes mellitus, hypertension, hyperlipidemia, chronic obstructive pulmonary disease (COPD), current smoking, previous smoking, chronic renal insufficiency, end-stage renal disease, steroid use, or clopidogrel use was recorded. Wound site infection and dehiscence over a 30-day period were recorded. Involvement of the dermis and subcutaneous tissue constituted a superficial wound infection or dehiscence, whereas extension to the fascia level was defined as a deep wound complication.
Descriptive statistics were used to assess demographics, comorbidities, and operative parameters. A two-tailed Fisher exact test was used to compare characteristics for categorical variables and two-tailed t-test for normally distributed continuous variables. Multivariate regression analysis was performed to adjust for confounders and identify potential risk factors for developing wound complications. P < .05 was considered significant. The analyses were carried out using Stata (version 11.2; StataCorp, College Station, Tex).
RESULTS
Both groups had similar demographics and clinical characteristics (Table I) . There were 211 patients in group A and 243 patients in group B. No significant difference in the prevalence of comorbidities, such as CAD, diabetes mellitus, hyperlipidemia, COPD, current smoking, previous smoking, chronic renal insufficiency, or perioperative systemic steroid or clopidogrel use, was noted between the two groups. There was a higher prevalence of hypertension in group B (86.7% vs 93%; P ¼ .028). The difference in nasal MRSA prevalence was not significant between the groups (6.1% vs 6.7%; P ¼ .701).
There was no significant difference in the distribution of vascular procedure type, conduit type, operative blood loss, or perioperative blood transfusion rates between the two groups. However, the mean operative time was longer in group B (263 minutes vs 299 minutes; P < .001; Table II ). Preoperative antibiotic prophylaxis was similarly distributed between the groups, with the majority of patients in either group having received intravenous vancomycin (92.9% vs 95.5%; P ¼ .311; Table III ). Alternative antibiotics, such as b-lactams or carbapenems, were administered in the event of patient allergy or when concurrent coverage for unrelated concomitant infections was necessary.
Looking at 30-day wound complication rates (Fig), a total of 53 patients in group A (25.1%) developed either superficial or deep wound infections compared with 42 patients in group B (17.2%; P ¼ .049). The difference was primarily due to group A demonstrating a higher rate of superficial infections than group B (18.9% vs 11.5%, respectively; P ¼ .033). There was no significant difference in deep wound infection rates between groups A and B (6.1% vs 5.7%, respectively; P ¼ .692).
Overall wound dehiscence was observed more commonly in group A patients (22.2%) than in group B (17.7%), but the difference did not reach statistical significance (P ¼ .239). The majority of the cases recorded were due to superficial dehiscence (21.3% vs 15.2%; P ¼ .113), whereas deep dehiscence was far less common for groups A and B (0.9% vs 2.4%; P ¼ .306). Early prosthetic conduit explantation was required in two group A patients and three group B patients. No major amputations were performed in the 30-day postoperative period as a result of wound complication.
In approximately 23% of all cases, there was history of prior open surgery involving the ipsilateral inguinal area. Subgroup analysis showed no significant difference between the reoperated patients and first-time operated patients with regard to superficial infections (12% vs 17.3%; P ¼ .502), superficial dehiscence (23% vs 19%; P ¼ .374), or deep dehiscence (1% vs 1.9%; P ¼ 1.0). However, there was higher rate for deep infections for the reoperated patients overall (13.1% vs 3.5%; P ¼ .020) without difference between groups A and B (6.6% vs 5.3%; P ¼ .691).
Bacteriologic data obtained from wound cultures demonstrated balanced distribution between the groups (Table IV) . The majority of documented infections in both groups were due to gram-negative organisms (13.2% vs 14.3%; P ¼ .574) followed by MRSA and other gram-positive cocci. In a significant number of cases (54%), empiric antibiotic treatment was instituted after clinical diagnosis of superficial wound complications.
On multivariate analysis, there was an increased risk of infection among patients with COPD (odds ratio [OR], 1.78; P ¼ .024) and increased body mass index (BMI) (OR, 1.09; P < .001; Table V) . There was also an even Table I were not found to be significant predictors of wound complications.
DISCUSSION
Vancomycin is a bactericidal glycopeptide that inhibits cell wall synthesis by binding to a D-alanyl-D-alanine cell wall precursor necessary for peptidoglycan cross-linking. Utilization of this agent has increased dramatically due to the growing prevalence of methicillin-resistant staphylococcal infections. However, limited data are available regarding its concentration in biological fluids other than plasma. Vancomycin is widely distributed to most tissues, with an approximate volume of distribution of 0.4 to 1 L/kg, and about 50% of it is protein bound. It is not metabolized and is primarily excreted unchanged in the urine via glomerular filtration. 3 Topical vancomycin has been hypothesized to achieve a higher local concentration of antibiotic avoiding toxic systemic doses, and decreasing the risk of associated bacterial resistance. 4 However, the degree to which vancomycin is absorbed systemically when applied in this topical fashion is fairly variable. 5, 6 There are data supporting the use of local vancomycin for the prevention of sternal wound infections in cardiac surgery. Vander Salm et al 2 first reported in 1989 the use of topical vancomycin applied to the sternum before skin closure in a blinded, prospective, randomized trial involving 416 cardiac surgery patients. There was a significant reduction in the incidence of sternal infections from 3.6% to 0.45% in the group receiving topical vancomycin (P ¼ .02). Infection also correlated with longer operative times. A prospective single-arm study by Desmond et al 5 studied the effect of topical vancomycin before sternotomy closure on systemic vancomycin levels in 14 patients undergoing elective coronary artery bypass graft procedures. Serum levels were measured at 30, 60, 120, 180, and 720 minutes. They found that topical vancomycin administration correlated with detectable although subtherapeutic systemic vancomycin levels for up to 5 days postoperatively. In another study, Lazar et al 6 concluded that the use of topical vancomycin applied to the sternotomy incision did not potentiate the Values are represented as n (%). emergence of drug-resistant infections or contribute significantly to postoperative renal toxicity.
In the neurosurgical literature, direct deposition of vancomycin powder has been reported to significantly reduce the incidence of infection in patients undergoing posterior spine stabilization for traumatic spine injuries as well as other neurosurgical spine procedures. 7, 8 The orthopedic literature also supports the use of local antibiotics in the form of cement beads or via orthopedic implants for the treatment of infected open fractures and osteomyelitis. 9, 10 In vitro studies have also demonstrated that such delivery media avoid high concentrations of antibiotics, which would otherwise inhibit bone healing. 11 In addition, animal model studies evaluating the effectiveness of sustained-release vancomycin sheets, vancomycin-delivering glycerylmonostearate implants, or vancomycin-coated mesh have also demonstrated significantly reduced rates of bacterial growth in the presence of local antibiotics. [12] [13] [14] Currently, it is unknown whether local vancomycin treatment has any effect on wound complications after vascular procedures. The reported incidence of surgical wound infections after vascular surgery ranges from 2% for open or endovascular aortic interventions to as high as 20% after lower limb bypass grafting procedures. 1 Wound infections may dramatically increase health care resource utilization and further increase morbidity, especially in patients with vascular reconstructions. Deep infections and dehiscence risk exposure of underlying vascular grafts and may necessitate graft removal or at least multiple procedures if graft salvage is pursued. 15 With the high cost of managing the sequelae of postoperative wound complications and the health care system's growing emphasis on paying for performance, it is important to investigate methods of reducing such complications.
Our study showed a 7.9% decrease in overall inguinal wound infection rates for the local vancomycin therapy group. This difference mainly reflects a positive impact on superficial infections as the decrease in deep infection rates was 0.4% and not statistically significant. In a similar fashion, the trend toward a decrease in overall dehiscence by 4.5% for the local vancomycin group was not statistically significant and was driven primarily by superficial dehiscence events.
The benefit of local vancomycin in our cohort was small and related to superficial wound complications, which is in contrast to the benefit reported in median sternotomy studies. This may be due to differences between sternal and inguinal wound characteristics. The former has a rich vascular supply involving the sternal bone marrow and crossing pectoralis major muscle fibers, whereas the latter is primarily composed of subcutaneous adipose and lymphatic tissue. The decreased vascularity encountered in the inguinal wounds could result in poor systemic absorption of the local antibiotic compared with median sternotomy wounds.
Another contributing factor to the blunted comparative benefit of local vancomycin observed in our series could be that the majority of patients received preoperative intravenous vancomycin due to the increased prevalence of MRSA in our institution's patient population (6.3%). Approximately half of the infections, all of which were superficial, were diagnosed and treated empirically with gram-positive coverage antibiotics. For the remainder of superficial infections, as well as all deep complications in either group, gram-negative organisms were identified as the most common pathogens followed by gram-positive cocci.
Factors associated with increased risk of both infection and dehiscence included BMI and history of COPD. We found a 9% risk increase per 1 kg/m 2 of BMI above normal. It is possible that obese patients are prone to inguinal complications due to compromised local hygiene, need for deeper lymphatic bed dissection to expose femoral vessels, and increased lateral wound traction forces as noted by other authors as well. 16, 17 Underlying pathologic correlation in patients with COPD and chronic kidney disease seems more complex, as these patients also have impaired immune response and wound healing. 16, 18, 19 The protective effect seen in patients with CAD is likely indirect and Limitations of the present study should be mentioned. It is a retrospective study focusing on wound complications within the 30-day postoperative period, not accounting for possible late infections. However, the incidence is expected to be very low because most surgical wounds are completely healed by this point. Local vancomycin was administered at the surgeon's discretion, which may have introduced selection bias, although both groups had balanced distribution of clinical and operative variables. Serum vancomycin levels were not measured in our patients; thus, the rate of absorption and bioavailability cannot be determined for the specific wound bed application.
CONCLUSIONS
Our study demonstrates that the addition of intraoperative local vancomycin did not improve the rates of inguinal wound dehiscence or deep infections but did have a positive impact on superficial wound infections and might be considered in high-risk patients. Modification of identified risk factors may further decrease the incidence of inguinal wound complications. A prospective randomized study is needed to further evaluate the role of local vancomycin treatment on inguinal wound outcomes.
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